Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drops could replace reading glasses for millions

NCT ID NCT05656027

Symptom relief Sponsor: LENZ Therapeutics, Inc Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an eye drop called LNZ101 to help people with presbyopia (age-related trouble seeing up close) read without glasses. 469 adults aged 45-75 received the drops, and researchers measured how many gained clear near vision without losing distance vision on the first day. The goal was to see if the drops are safe and effective for temporary symptom relief.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

469 people

The number who actually took part.

Started

Dec 2022

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign a Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend all study visits; 3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1; 4. Have +1.00 to -4.00 diopter (D) of sphere calculated in minus cylinder (so that spherical equivalent (SE) results in myopia no more severe than -4.00 D MRSE) in both eyes determined by manifest refraction documented at Visit 1; 5. Have ≤2.00 D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1; 6. Be presbyopic as determined at Visit 1 Exclusion Criteria: Subjects must not: 1. Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy; 2. Have known contraindications or sensitivity to the use of any of the study medications or their components; 3. Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation in either eye; 4. Have moderate or severe dry eye defined as total central corneal fluorescein staining in either eye at Visit 1; 5. Have clinically significant abnormal lens findings including early lens changes in either eye during dilated slit lamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eye diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eye disorder myopia presbyopia refractive error

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Eye diseases Near vision Presbyopia Refractive error

Contacts and locations

Locations

  • Site #101

    Glendale, California, 91204, United States

  • Site #102

    Mt. Dora, Florida, 32757, United States

  • Site #103

    Kingston, Pennsylvania, 18704, United States

  • Site #104

    Fargo, North Dakota, 58103, United States

  • Site #106

    Chandler, Arizona, 85224, United States

  • Site #107

    Petaluma, California, 94954, United States

  • Site #108

    Pittsburg, Kansas, 66762, United States

  • Site #109

    Littleton, Colorado, 80120, United States

  • Site #110

    Garden Grove, California, 92843, United States

  • Site #111

    Santa Barbara, California, 93105, United States

  • Site #112

    Smyrna, Tennessee, 37167, United States

  • Site #116

    Memphis, Tennessee, 38104, United States

  • Site #118

    Rock Island, Illinois, 61201, United States

  • Site #119

    San Antonio, Texas, 78229, United States

  • Site #121

    Mesa, Arizona, 85202, United States

  • Site #122

    Phoenix, Arizona, 85032, United States

  • Site #123

    San Antonio, Texas, 78229, United States

  • Site #124

    Phoenix, Arizona, 85053, United States

  • Site #125

    Sun City, Arizona, 85351, United States

  • Site #126

    Rancho Cordova, California, 95670, United States

  • Site #127

    Overland Park, Kansas, 66210, United States

  • Site #128

    Scottsdale, Arizona, 85260, United States

  • Site #129

    Newport Beach, California, 92663, United States

  • Site #130

    Azusa, California, 91702, United States

  • Site #131

    Rochester, New York, 14618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.